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Abstract
While the cost and speed of generating genomic data have come down dramatically in recent years, the slow pace of
collecting medical data for large cohorts continues to hamper genetic research. Here we evaluate a novel online framework
for obtaining large amounts of medical information from a recontactable cohort by assessing our ability to replicate genetic
associations using these data. Using web-based questionnaires, we gathered self-reported data on 50 medical phenotypes
from a generally unselected cohort of over 20,000 genotyped individuals. Of a list of genetic associations curated by NHGRI,
we successfully replicated about 75% of the associations that we expected to (based on the number of cases in our cohort
and reported odds ratios, and excluding a set of associations with contradictory published evidence). Altogether we
replicated over 180 previously reported associations, including many for type 2 diabetes, prostate cancer, cholesterol levels,
and multiple sclerosis. We found significant variation across categories of conditions in the percentage of expected
associations that we were able to replicate, which may reflect systematic inflation of the effects in some initial reports, or
differences across diseases in the likelihood of misdiagnosis or misreport. We also demonstrated that we could improve
replication success by taking advantage of our recontactable cohort, offering more in-depth questions to refine self-
reported diagnoses. Our data suggest that online collection of self-reported data from a recontactable cohort may be a
viable method for both broad and deep phenotyping in large populations.
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Introduction
In the last few years, the cost of collecting genomic data has
declined rapidly. However, advances in the collection of phenome
data (the set of all phenotypic information from a single organism)
have not kept pace [1,2]. New techniques are needed to
complement the wealth of genomic data and build the large
cohorts needed for highly-powered genome-wide association
studies (GWAS).
The reliability of phenotyping is important for GWAS.
Phenotyping error decreases power, which can be problematic
as most GWAS are not sufficiently powered to explain a significant
fraction of the underlying heritability. Although increasing sample
sizes can counteract the problems caused by misclassification, it is
the very issue of needing ever larger samples that necessitates more
efficient methods for collecting data [3]. A number of associations
reported in very large meta-analyses have not been replicated, and
may never be, simply because of the difficulty of assembling such a
sizeable cohort of patients. There is a need for more straightfor-
ward methods to quickly and reliably gather retrospective
phenotype information from large cohorts of people, not only to
validate existing associations, but to discover new ones.
Although self-report has frequently been used for physical traits,
medical records have traditionally been the preferred source of
retrospective information on medical conditions. Previous studies
have reported good agreement between medical record data and
self-reported medical conditions [4–8], and include a few common
themes. First, there tends to be good concordance for well-defined
and easily diagnosed diseases and for chronic conditions that
require repeated medical follow-up (kappa ranging from 0.71–0.80
for diabetes, hypertension, myocardial infarction, and stroke) [4–
9]. Second, a negative self-report is very likely to agree with a
negative result from the medical record [5]. Third, self-reports of
conditions that are milder, less specific (such as heart failure), or
communicated in different ways by physicians (such as high
cholesterol) tend to be less consistent with medical records,
possibly because the original diagnosis was less certain or because
of insufficient physician—patient communication [4,8,10]. Fourth,
medical records, especially in countries without centralized
healthcare, typically only address diseases from a limited portion
of a patient’s life; self-report can be more accurate for diseases
outside this window [5].
To begin to address the phenomics problem, a structure that
facilitates both broad and deep phenotyping and maximizes the
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participants is needed. In this study, we evaluate a research model
in which a large, recontactable cohort is surveyed online across a
broad range of phenotypes. Subsets of this cohort with particular
characteristics can then be contacted for further research with
more in-depth phenotyping on specific topics as appropriate. We
have demonstrated previously that this model can be used to
discover and replicate associations with non-medical traits [11].
Here, by assessing our ability to replicate previously reported
genetic associations across a wide range of conditions, we
demonstrate that broad self-reported data collection online is
useful for medically-related conditions as well. We show that some
classes of conditions lend themselves particularly well to simple
self-report, while others are more complex. We also show that the
ability to recontact the cohort facilitates rapid refinement of
phenotype characterization.
Results
We sought to replicate associations from the list curated by the
National Human Genome Research Institute’s Office of Popula-
tion Genomics (‘‘GWAS catalog’’) in a cohort of 20,182
participants of European ancestry who filled out surveys on the
23andMe website [12,13]. Members of the cohort, drawn from the
23andMe customer base, had been genotyped at approximately
600,000 SNPs, and had access to their raw genetic data as well as
health- and ancestry-related interpretations of their data. The
majority of the cohort was not selected based on disease status or
other characteristics and is roughly a representative sample from
the 23andMe customer base; approximately 4,000 members of the
cohort had been recruited for a study on Parkinson’s disease or a
project with the National Senior Games Association (http://www.
nsga.com/).
Phenotypes from the GWAS catalog were matched with available
phenotypes from the online surveys (see Methods). In order to collect
data on a wide range of phenotypes while keeping the time spent
answering surveys low, we chose to assess most phenotypes using
only single questions of the general form ‘‘Have you ever been
diagnosed bya doctorwith [Condition X]?’’.A total of50 conditions
from the GWAS list had direct analogues within the 23andMe
database. For each condition, we used only one SNP from each
linkage disequilibrium (LD) block (using a threshold of r
2.=0.1)
and removed SNPs that were not on our platform or did not have a
proxy SNP on our platform with LD of r
2.=0.5. Ultimately, we
attempted to replicate a total of 392 different associations (315
case—control, 77 quantitative) for these 50 phenotypes.
Using a one-sided P,0.05 threshold for significance, we
replicated 144 (93 case—control and 51 quantitative) of the 392
attempted associations in 36 of the 50 phenotypes (Figure 1, Table
S1, Table S2). For some conditions, the size of our case group was
quite small; however, the odds ratios for replicated SNPs were
generally in good agreement with the published odds ratios. Of the
case—control conditions, 84.6% of the replications had 95%
confidence intervals containing the published odds ratio (replica-
tions for pigmentary phenotypes such as eye color, hair color, and
freckling were not included as the assessment scales are not easy to
match across different published reports). As one aspect of
23andMe’s Personal Genome Service involves returning genetic
data to our customers, we investigated the possibility that
customers viewing a result of elevated risk for a certain disease
before answering surveys may skew the results towards replication.
To address this, we investigated the impact of seeing genetic risk
results before versus after answering survey questions on self-
reported disease status for a set of 20 conditions for which
participants were able to view a personal risk prediction. We
observed that in general, the nature of the genetic risk result did
not have a consistent or significant effect on the way questions
were answered (Table S4).
As many of the known associations were discovered in large
case—control studies, we expected to have low power to detect
many of them using our mostly unselected cohort. Thus, to further
assess our success in replication, we calculated our power to
replicate each association for all case—control phenotypes
(quantitative phenotypes were skipped in this calculation due to
difficulties in matching scales in many of them). Power was
calculated using the odds ratios reported in the GWAS catalog. To
allow for phenotyping error, the calculations assumed that 5% of
our reported cases are actually controls and that the minimum of
the prevalence or 10% of our controls are (or will someday be)
cases. For diseases with over 10% prevalence, controls were
generally chosen to be of sufficient age so that at most 10% of
people without the disease at that age would be expected to
develop the disease. See Methods for full details.
We replicated 70% of the number of replications expected (93
replications against 132.7 expected), given our sample sizes
(Figure 2). Some of the failed replications can be traced back to
the possibility that the reported effect sizes for these associations
are inflated or that the associations themselves are false positives.
Table 1 shows all associations for which we had at least 80%
power to replicate but failed to do so. Of these 19 associations, five
have failed to replicate elsewhere despite high power to do so, two
have shown significant heterogeneity of odds ratios in meta-
analyses, and two exhibited significant signals when the two stages
of a multi-stage study were combined but were not interpreted as
significant by the authors. Removal of these nine SNPs for which
our power may be substantially overestimated increased our
replication rate to about 75% (93 out of 124.0). Furthermore,
among the remaining 213 SNPs that we did not replicate, we
observed the correct directionality of association for 126 out of an
expected 172.0 SNPs (using a p-value threshold set to 0.5), yielding
a rate of 73.2% relative to expected. Interestingly, an inflamma-
tory bowel disease (IBD) association (rs7517847) that we had high
power to replicate also failed to replicate in ulcerative colitis only
cases in an Italian study of IBD, suggesting that the association
may be specific to Crohn’s disease, as opposed to all types of IBD
[14]. Overall, our success rates differed vastly for different classes
of diseases (Figure 2, Figure S1), suggesting that the difference
between theoretical and actual power is to some extent explained
by differences in phenotyping (discussed in more detail below).
Separate from these calculations, we also attempted to replicate
106 associations with phenotypes in our cohort that were only in
weak correspondence with phenotypes in the published papers. Of
the 106, we replicated 39 associations. For example, while we did
not collect data on gallstones, we did collect data on gall bladder
surgery which is often a consequence of gallstones, and were able
to replicate one association with gallstones. Likewise, answers to
the question ‘‘Have you ever been diagnosed by a doctor with high
cholesterol (over 200 mg/dl) or hypercholesterolemia?’’ were
sufficient to replicate 19 associations with cholesterol level. Data
on receiving an abnormal result on a liver function test result were
sufficient to replicate four associations with bilirubin levels. A
summary list of these replications can be found in Table 2 (full list
in Table S3).
Discussion
Advances in technology have driven down the price and
difficulty of genotyping, but until recently, the same has not been
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Efficient Replication of over 180 AssociationsFigure 1. Replicated SNPs for binary traits. Our log ORs and 95% confidence intervals are shown as black circles and lines. Published ORs are
shown as blue Xs.
doi:10.1371/journal.pone.0023473.g001
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23473Figure 2. Success rate (versus total power) by disease class. Replications=number of associations we successfully replicated.
Expected=number of associations we expected to replicate. Attempts=number of associations we attempted to replicate. The blue dot represents
our success ratio (number of successful replications divided by number of expected replications). The black line represents the 95% prediction
interval for the success ratio. The nine associations that we had high power to detect but had known conflicting data were not included in this figure
(see text and Table 1). Conditions assigned to each class (also see Methods S1): Asthma: childhood asthma; Autoimmune: Crohn’s disease,
inflammatory bowel disease, lupus, multiple sclerosis, psoriasis, type 1 diabetes, ulcerative colitis; Cancer: basal cell carcinoma, bladder cancer, breast
cancer, colorectal cancer, prostate cancer, lung cancer, melanoma, pancreatic cancer, scleroderma, testicular cancer, thyroid cancer; Celiac: celiac
disease; Diabetes: type 2 diabetes; Heart: blood clots, coronary artery disease, heart attack; Pigment/Hair: eye color, freckling, hair color, red hair color,
male pattern baldness; Neuro: Alzheimer’s disease, autism, Parkinson’s disease; Other: chronic obstructive pulmonary disease, kidney stones, stroke,
osteoarthritis; Psychiatric: alcohol abuse, bipolar disorder, schizophrenia.
doi:10.1371/journal.pone.0023473.g002
Table 1. Associations with sufficient power for detection (.=80%) that failed to replicate.
Phenotype SNP Pub OR Rep OR P-value Power Cases Controls
Replications in the
Literature
Alcohol abuse rs7590720 1.35 0.955 0.875 1 1811 8549 Failed to replicate [30]
Bipolar disorder rs1012053 1.59 1 0.485 1 366 13030 Failed to replicate [31–34]
Bipolar disorder rs420259 2.08 0.966 0.659 1 366 13030 Failed to replicate [32–34]
COPD
a rs13180 1.3 1.05 0.26 0.89 403 2306 Replicated [35]
COPD
a rs7671167 1.32 1.11 0.0968 0.93 403 2306 Replicated [35]
COPD
a rs1828591 1.38 1 0.489 0.97 403 2306 Replicated [36,37]
Crohn’s disease rs2066847 3.99 1.54 0.151 0.88 84 13288 Replicated [38]
IBD
b rs7517847 1.61 0.855 0.954 1 250 12808 Replicated [39]
c
Juvenile allergic asthma rs2786098 1.43 1.07 0.181 1 641 6584 Failed to replicate [40]
Lupus rs3131379 2.36 1.38 0.133 0.82 52 11675 Not yet replicated
Parkinson’s disease rs17115100 1.25 0.992 0.555 0.97 2274 5336 Not claimed [41]
d
Parkinson’s disease rs823128 1.52 1.17 0.0531 1 2274 5336 Not claimed [41]
d
Psoriasis rs20541 1.27 1.09 0.0953 0.92 833 4291 Replicated [42,43]
Rheumatoid arthritis rs10499194 1.33 0.927 0.797 0.9 308 12845 Failed to replicate [44]
Rheumatoid arthritis rs3761847 1.32 1.01 0.437 0.93 308 12845 Between-study
heterogeneity [45]
Type 2 diabetes rs9300039 1.48 0.976 0.595 0.97 778 3273 Between-study
heterogeneity [46]
Type 2 diabetes rs2943641 1.19 1.03 0.328 0.81 778 3273 Not yet replicated
Thyroid cancer rs965513 1.75 1.37 0.0559 0.83 52 11234 Replicated [47]
Ulcerative colitis rs11209026 1.79 1.47 0.0577 0.85 181 13100 Replicated [48]
Pub OR=published odds ratio. Rep OR=23andMe attempted replication odds ratio. Power=estimated power to detect association.
aCOPD=Chronic Obstructive Pulmonary Disease. This analysis included smokers only.
bIBD=Inflammatory Bowel Disease.
cThis SNP was initially associated with IBD, but replicated only for Crohn’s disease [39], which is a subtype of IBD. Latiano et al. also replicates rs7517847 with Crohn’s
disease, but not with ulcerative colitis, which is the other major subtype of IBD [14].
dThis association was curated into the GWAS catalog as significantly associated with Parkinson’s disease but was not identified by the authors as significant.
doi:10.1371/journal.pone.0023473.t001
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self-reported data on medical phenotypes is an efficient and
effective method for phenotyping a large cohort of individuals, as
evidenced by our ability to replicate a high percentage of
associations across a wide range of conditions. Relative to medical
record review, internet-based phenotyping is fast (we assessed
more than 20,000 people for 50 phenotypes in approximately 12
months using only a small team of people). To our knowledge, this
is the largest number of replications across a wide variety of
diseases ever reported, demonstrating the value of gathering self-
reported data on a large genotyped population.
While many of the associations tested here have been replicated
before, there are a few that are, based on our literature review, the
first independent replications of these associations in a population
of European descent: basal cell carcinoma (PADI4, RHOU), plasma
levels of liver enzymes (PNPLA3), and bone mineral density
(MEF2C, MEPE—these have already been replicated in a
population of Asian descent). Though our study has been
performed in a population of European ancestry, a similar study
would be feasible in other populations. Such a study could
potentially improve risk prediction in non-European populations
as well as further our understanding of disease architecture (e.g.,
understanding how effect size varies across populations could
provide insight into how tightly linked associations are to the
causal variants). Furthermore, while it is true that we are able to
replicate previously identified associations using our research
platform, the reverse is also true—novel discoveries using our
method have been independently replicated using other modes of
data collection for both traits and medical conditions [16–19].
Although most studies use medical records as the gold standard
against which self-reported data are compared, there are some
inherent challenges to the use of medical records [5]. As very few
people have received all their health care from the same provider,
the medical records from different stages of their lives are stored at
different sites of care. Thus, a childhood diagnosis of asthma might
be stored in a record at the pediatrician’s office but not be reported
in the record at the adult medical practice. In addition, extracting
data from medical records often requires either manual curation,
which is time-consuming and expensive, or reliance on ICD-9-CM
or CPT codes which may have been miscoded. For example, a
replication study was carried out using the BioVU DNA databank
at Vanderbilt University by applying natural language processing
techniques and billing-code queries to electronic medical records
[20]. Their algorithms achieved high positive predictive value (as
measured by independent record review by two physicians) but
required manual review and significant iterative work. Out of 21
SNPs in five phenotypes, they were able to replicate eight
associations. In contrast, we were able to examine 50 phenotypes
and replicate over 180 associations. For cases in which the
information required may be difficult for individuals to report but
can be extracted from electronic medical records (such as lab
values), these two methods can provide complementary sources of
data.
We replicated approximately 75% of the associations we
expected to (excluding those for which our power may be
substantially overestimated), based on power calculations. There
are several possible reasons why we did not replicate all the
associations we expected to (see Figure 2 and Figure S1 for
instances in which our success ratio did not overlap the 95%
prediction interval). One factor is systematic inflation of odds
ratios in the initial reports due to the winner’s curse—a bias in the
effect size estimates from the first publication to report an
association, generally occurring when the discovery sample is
poorly powered to detect the association [21]. For example, if we
were to assume a systematic inflation of 15% in the log-odds ratio,
the replication rate would change from 70% to 77% (or 75% to
82% if we again exclude the nine associations that are not clearly
true positives). This amount of inflation is entirely within the
confidence intervals for most studies: it corresponds to an
estimated odds ratio of 1.3 where the true odds ratio was 1.25
or an estimate of 1.5 where the true odds ratio was 1.41. There are
more sophisticated methods to perform bias correction for odds
ratios but these require an analysis of the original experimental
design that is beyond the scope of this paper [22].
While winner’s curse probably explains part of the deviation
from expected, some classes of diseases were likely not well
phenotyped in this study, through some combination of misdiag-
nosis and misreport. For example, autoimmune diseases are more
challenging because they may be of low prevalence, have non-
specific symptoms, and a high rate of misdiagnosis. In a study of
rheumatoid arthritis diagnoses by non-rheumatologists, 23–82%
were judged to be misdiagnoses [23], while another study showed
that relative to assessment in a specialist setting, patients in a
community setting who received a diagnosis of celiac disease were
actually misdiagnosed more than 50% of the time [24]. Some of
the underperformance of this approach for autoimmune diseases is
Table 2. Replications without strictly matching phenotypes.
23andMe Phenotype Published Phenotype # Replications Genes
Liver test Bilirubin levels 4 CHUK, GGT1, SAMM50, UGT1A1
High cholesterol Cholesterol levels (quantitative)
a 19 ABCG8, APOA1, APOB, CELSR2, CILP2,
DNAH11, DOCK7, FADS1, GCKR, HNF1A,
LDLR, LIPC (62), MAFB, NCAN, PCSK9 (62),
TOMM40, TRIB1
Gall bladder removal Gallstones 1 ABCG8
High blood pressure Blood pressure (quantitative)
a 8 ATP2B1, CYP17A1 (62), CYP1A1, FGF5,
SH2B3, ULK4, ZNF652
Osteoporosis Bone mineral density (quantitative)
a 5 MEF2C, MEPE, OSX, SOX6, SPTBN1
Macular degeneration Advanced age-related macular degeneration 2 C2, C3
Nicotine abuse Nicotine dependence 1 CHRNA3
aThese phenotypes were measured quantitatively in the published reports, but the corresponding 23andMe phenotypes listed here were measured qualitatively (yes/
no).
doi:10.1371/journal.pone.0023473.t002
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non-specialist.
Because we chose to keep the burden of answering surveys low
for our participants, many of the conditions in this study were
assessed with single questions such as ‘‘Have you ever been
diagnosed by a doctor with schizophrenia?’’ This assessment likely
led to reporting errors for some diseases. For example, psychiatric
diseases or mental disorders such as Alzheimer’s disease, for which
diagnosis requires a somewhat subjective clinical evaluation of a
patient’s symptoms or an autopsy, were each assessed via a single
question in this study. More questions are needed here to gather
information about the clinical features that led to the diagnosis. In
addition, in some cases it may make more sense to have a family
member, friend, or caregiver provide information for an
individual.
On occasion, the nature of people’s answers to such single
questions necessitated making judgment calls on how to define a
phenotype. Because some people may have type 2 diabetes but
are only aware of having high blood sugar, we included people
who self-reported having hyperglycemia as type 2 diabetes cases.
For chronic obstructive pulmonary disease (COPD), we included
individuals who reported having emphysema or chronic bron-
chitis. However, there are likely to be individuals who repeatedly
get bronchitis associated with a cold or flu and reported having
‘‘chronic bronchitis’’, not knowing that the clinical definition of
this condition is developing bronchitis lasting at least three
months in two consecutive years. This confusion may have
reduced our power to replicate associations with COPD. In other
cases, we were unable to come up with an acceptable match for a
condition. For example, most GWAS of age-related macular
degeneration (AMD) have focused on advanced AMD and
generally only included cases with large drusen, geographic
atrophy, and/or neovascularization. Our question asked only
about AMD without assessing severity and thus our study may
have included individuals with small or intermediate drusen and/
or pigmentary abnormalities as cases. Such phenotypes from the
GWAS catalog without direct analogs in our database were
skipped for the main calculations in this paper. For all such
conditions, more in-depth questions will be necessary to collect
data more accurately.
These in-depth questions, which will be important when
attempting to unravel the complex biological underpinnings of
most phenotypes, can be asked up front for phenotypes that we
suspect a priori may be challenging to assess. However, having a
recontactable cohort makes the process of refinement possible
when more information must be gathered. For celiac disease,
starting with the question ‘‘Have you ever been diagnosed by a
doctor with celiac disease?’’, we replicated only one association out
of almost six expected. As the prevalence of celiac disease in our
cohort appeared to be somewhat higher than the reported
prevalence in the United States [25], we chose to return to our
customer database with a refined question of ‘‘Have you ever been
diagnosed with celiac disease, as confirmed by a biopsy of the
small intestine? If your diagnosis was not confirmed by a biopsy,
please select no.’’ As a result, with a much smaller number of cases
(which also reduced the number of associations we expected to
replicate), we successfully replicated 4 out of 4.5 associations
expected for celiac disease. This approach could also be used to
examine endophenotypes or to divide broad phenotypes into
subclasses with more defined characteristics.
The trend in GWAS research has been towards ever increasing
sample sizes and reuse of previously genotyped cohorts whenever
possible. Because it is relatively straightforward for our participants
to provide information that is relevant for a variety of studies, any
given individual can be a case or a control in multiple analyses at
once. This could potentially reduce the total amount of work for
the patient (sample collection needs to occur only once to
participate in many studies) as well as potentially reducing the
total number of people an investigator needs to genotype. In
addition, for most conditions, this framework leads to a much
larger number of controls than cases, which increases the study’s
power up to a certain point. Though self-report may lead to a
slight increase in phenotyping error, in many cases, the lower
phenotyping cost may lead to a more powerful study. For example,
a study with 3,000 cases and 3,000 controls and a phenotyping
error rate of 5% would have 77% power to detect a SNP at a
minor allele frequency of 30% and an odds ratio of 1.3 with a p-
value threshold of 10
27. But a study with 5,000 cases and 5,000
controls with a phenotyping error rate of 10% would have 95%
power to detect such an association. Even if the error rate were
15%, the 10,000 person study would have 77% power and would
have many more people to follow up with. Although more data are
needed to evaluate the true costs of this model relative to other
models, we believe that this method has the potential to collect
high-quality phenotype data in an efficient manner.
The framework described here, in which additional questions
can be directed at participants at any time with relatively low
marginal effort, facilitates follow-up on specific topics as shown
in the celiac disease example. Thus, one possible model for large-
scale phenotyping could start with broad but shallow phenotyp-
ing by self-report on a very large cohort of individuals, followed
by targeted recontact of specific subsets of individuals for deeper
phenotyping based on the initial information gathered. The
additional phenotyping could involve more in-depth questions to
the participants or a completely different type of data collection
that may require an in-person visit. A platform like this one that
maintains an ongoing relationship with the participants,
including sharing data with them, may motivate individuals to
participate and stay active in research (for example, more than
80% of our research participants have taken more than one
research survey).
There are many benefits to having a large, recontactable cohort.
Testing new hypotheses, following up on initial data, and assessing
the accuracy of different risk prediction models are easier when the
need to assemble a new cohort every time is obviated. This raises
the question, how large of a cohort is needed? With 20,000
generally unselected people, we expected to replicate approxi-
mately 40% of the associations that we tested. Only a 106increase
to 200,000 individuals would raise the expected proportion of
replications to 80%, and with a million the expected replication
rate would be more than 97%. A simple sum of the initial sample
sizes in the papers reported in the GWAS catalog totals nearly
1,400,000. This is clearly an overestimate of the number of
genotyped individuals as certain cohorts are reported in more than
one study, but even if only 70% of these individuals are unique,
this would constitute a resource of a million individuals with
genome-wide genotype data who may be interested in participat-
ing in further research if given the opportunity. Unfortunately,
because of the way research is currently done, these individuals
come from dozens of different cohorts and it would be impractical
if not impossible to recontact them all. As we move into studies
that require ever larger sample sizes, such as those investigating
gene—gene or gene—environment interactions, developing more
efficient methods of conducting this type of research will become a
necessity. We believe that this model in which investigators
maintain long-term relationships with research participants and
facilitate their participation through online tools is a significant
step in that direction.
Efficient Replication of over 180 Associations
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Cohort, Genotyping, and Phenotyping
Participants of European ancestry were drawn from the
customer base of 23andMe. This group is almost 58% male, with
an average age of 46 (approximately 95% of the group is between
the ages of 20 and 80). Most of our participants are from the
United States, with the next largest groups from Canada and
Europe. Genotyping was performed on the Illumina Human-
Hap550+ BeadChip and all SNPs tested had a call rate of at least
99%. All individuals provided informed consent and answered
surveys online according to our human subjects protocol, which
was reviewed and approved by Independent Review Consulting,
now part of Ethical & Independent Review Services, a private
institutional review board (http://www.eandireview.com). A
number of the surveys were based on existing instruments in the
literature; the remainder was developed by 23andMe scientists. In
general, the new questionnaires were designed in collaboration
with a medical professional and reviewed by an external scientific
group. All surveys were accessible to customers who had logged in
to their 23andMe accounts on a page labeled ‘‘Research Surveys’’.
Each survey was labeled with a descriptive title and a link to a
short explanation of the content and purpose of the survey.
Surveys could be taken in any order and at any time. Because of
this, the response rate (number of people who answered the survey
divided by all genotyped users who had consented to participate in
research, which is likely greater than the number of people who
ever viewed the survey) varied from survey to survey but was
generally in the range of 15–40%. The ‘‘Your Medical History’’
survey, from which the majority of the phenotype data used in the
study were collected, had a response rate of 39%. We used data in
our analysis that were collected prior to October 20, 2010.
Identification of SNPs for replication studies
The GWAS catalog is a list of genome-wide association studies
curated by the National Human Genome Research Institute’s
Office of Population Genomics [12,13], and is a relatively
complete catalog of SNPs found in published GWAS. We accessed
the catalog on May 10, 2010 and sought to replicate as many SNP
associations as possible from that list. We removed any SNPs from
the list with reported p-values greater than 10
27 to limit the
number of false positives we were attempting to replicate. In
addition, we required that the entry had a reported odds ratio or
regression coefficient and that the associations were to single
SNPs, rather than haplotypes. For this analysis, as most GWAS
are performed in populations of European descent, we restricted
our attention to those associations reported in European
populations to maximize the total number of associations we
could test. We removed duplicate associations from the list,
attempting to use the study with the largest total number of cases.
To further avoid testing the same association twice, for SNPs that
were in LD with each other (using a threshold of r
2.=0.1), we
only picked one association, again attempting to use the study with
the largest total number of cases. Where papers reported multiple
SNPs in LD with each other, we chose the SNP with the smallest
p-value. In cases where we did not have the reported SNP on our
platform or where the SNP was not called in over 99% of our
subjects, we used a proxy SNP if there was one with r
2.=0.5. We
did not use results reported from papers that included the
23andMe database. Original data from the GWAS catalog can be
found for all attempted replications with well-matching pheno-
types in Table S7, and for all successful replications with less
strictly matching phenotypes in Table S8.
Not all papers used the same stranding conventions, and some
papers have misreported the risk allele. Therefore, we checked the
stranding of the reported associations using a multi-step process.
First, we confirmed that the CEU HapMap frequency information
roughly matched the risk allele frequency reported in controls for
all SNPs. Specifically, if the reported risk allele frequency and the
HapMap frequency were both less than 0.35 or greater than 0.65,
the frequency was judged to match. Unambiguous SNPs (i.e.,
SNPs whose two alleles are not reverse complements) with
matching frequencies were judged to be correctly reported. All
ambiguous SNPs and SNPs without HapMap data were checked
manually in the original papers. This process turned up at least
one SNP whose risk allele could not be determined from the
original data (rs6457620 with rheumatoid arthritis, not replicated
here).
Finally, we required that we could define cases in essentially the
same manner as the original paper (using self-reported data for
clinical data, where applicable). For example, we restricted our test
to people in our database reporting disease onset before the age of
18 for associations to juvenile onset conditions. We also attempted
to match smoking status and sex when applicable. In several cases
the matching of diseases was a judgment call (for example, self-
reports of hyperglycemia and type 2 diabetes were both coded as
type 2 diabetes cases). For several common diseases, in an attempt
to maximize power, we restricted our set of controls using
incidence data for the disease. Specifically, we required controls to
be at an age advanced enough that 90% of the controls would be
expected never to develop the disease. See Methods S1 and Table
S6 for how phenotypes were defined.
Power calculations
We calculated power only for binary traits, using the model
from Freidlin et al. [26], modified to calculate power under a one-
sided test and to allow for phenotyping error (specified as the
percentage of cases incorrectly classified as controls, and vice
versa). We set error rates at 5% for cases, based on general
evidence that misdiagnosis rates are often over 5%. For example,
misdiagnosis rates have been estimated to be 30–45% for celiac
disease [24], 5% for multiple sclerosis [27], between 23% and 82%
for rheumatoid arthritis diagnosed by a non-rheumatologist [23],
and even for cancer with biopsy there are 1.4% discrepant
diagnoses when comparing the original diagnosis with a second
opinion [28]. We took the error rate for controls to be the
minimum of the disease prevalence and 10%. For associations
where we used a proxy SNP not in complete linkage disequilib-
rium with the original reported SNP, the total sample size was
scaled by r
2 in the power calculation [29].
Statistical methods
We calculated the p-values for binary associations using the
score test for a logistic regression (also known as the Armitage test).
Odds ratio (OR) and effect sizes are specified for the risk allele
reported in the GWAS catalog [12,13]. For non-binary traits, we
used the Wald test for a linear regression. We used a threshold of
0.05 for significance of any individual test. All tests were one-sided
in the direction of the published OR. Using different thresholds
did not change the results substantially (Table S5). There is no
substantial multiple testing burden in this study, as the vast
majority of the associations are probably true signals.
For the prediction intervals in Figure 2, we used a model in
which each attempted replication was considered to be an
independent Bernoulli event with success probability equal to
our estimated power for replicating that association. Using a
dynamic programming recurrence, we explicitly computed the
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replications based on this model. We then determined a 95%
prediction interval [L, U] for the total number of successful
replications by finding the largest L such that the probability of
observing fewer than L replications (or analogously, the smallest U
such that the probability of observing greater than U replications)
was at most 2.5%. Finally, we determined the reported prediction
intervals by dividing these lower and upper bounds by the
expected total number of successful replications.
To test whether having seen personal risk estimates for a disease
had an effect on self-report of that disease, we looked for an
interaction between reported disease risk and whether the
individual had possibly seen their report before answering the
question (Table S4). This was possible as many people filled out
surveys before their results became available. More precisely, we
regressed reported phenotype on predicted risk, a ‘‘results
available’’ indicator variable, the interaction of these two variables,
and age, sex and five principal components of ancestry, and tested
the interaction term for significance.
Supporting Information
Figure S1 Success rate (versus total power) by disease.
Replications=number of associations we successfully replicated.
Expected=number of associations we expected to replicate.
Attempts=number of associations we attempted to replicate. The
blue dot represents our success ratio (number of successful replications
divided by number of expected replications). The black line represents
the 95% prediction interval for the success ratio. For ovarian cancer,
the success ratio is 12.8 (not within the scale of the graph).
(DOCX)
Methods S1 Survey text. Unless otherwise noted, if multiple
questions were asked, any subject who answered positively (bolded
answer) to at least one was included as a case. Controls were those
who answered negatively to these questions. Individuals who gave
neitheranaffirmativenora negativereply(suchas‘‘I’mnotsure’’or
‘‘Decline to state’’) were not included in the analysis. A subject who
answered questions inconsistently (for example, yes to one breast
cancer question, no to another) was removed from that analysis.
Questions marked with ‘‘RS’’ were asked as Research Snippets,
which are questions that are asked singly, as opposed to being part
of a larger survey. For additional parameters, see Table S6.
(DOCX)
Table S1 All binary replications attempted. Risk=risk
allele for original SNP. Chr=chromosome. log(OR)=23andMe log
odds ratio. Pub log(OR)=Published log odds ratio. Rep=replicated.
(DOCX)
Table S2 All quantitative replications attempted. Risk=risk
allele for original SNP. Size=number of participants. Chr=chromo-
some. Beta=23andMe beta (effect size). Rep=replicated.
(DOCX)
Table S3 All successful replications without strictly
matching phenotypes. Phenotype=23andMe phenotype. Pub-
lished=publishedphenotype.OR=23andMeoddsratio.
aNote that
t h i sr e p l i c a t i o ni si nt h eo p p o s i t ed i r e c t i o nf r o mt h a tr e p o r t e di nt h e
GWAScatalog.However,aclosereadingofthe originalreport shows
that the direction of the effect was misreported in the GWAS catalog.
(DOCX)
Table S4 Effect of viewing genetic risk data on reported
disease status. Because one aspect of 23andMe’s Personal
Genome Service involves returning genetic data to our customers,
it is possible that viewing a result of elevated risk for a certain
disease may make it more likely for an individual to recall a
previous diagnosis of that disease, thus potentially skewing the
results towards replication. To address this, we investigated the
impact of seeing genetic risk results before versus after answering
survey questions on self-reported disease status for a set of 20
conditions for which participants were able to view a personal risk
prediction. Only for psoriasis was there a statistically significant
impact of seeing one’s results on self-report of disease status, and
this impact was no longer observed once the direction of the
estimated risk (increased or decreased) was taken into account,
suggesting that in general, the nature of the genetic risk result did
not have a consistent or significant effect on the way questions
were answered. Estimated Risk=p-value for association of
estimated risk with reported disease status. We expect to see an
association with any risk model that is reasonably predictive. Saw
Data First=p-value for association of viewing genetic risk results
before answering survey questions with reported disease status.
Estimated Risk * Saw Data First=p-value for association of
interaction between estimated risk and viewing this risk before
answering survey questions with reported disease status.
(DOCX)
Table S5 Success rate by replication p-value threshold.
Alpha=p-value threshold for replication. Replications=number
of associations successfully replicated. Expected=number of
associations we expected to replicate. Ratio=expected / replica-
tions. These calculations do not include the nine associations for
which our power may be substantially overestimated.
(DOCX)
Table S6 Additional parameters for phenotype classifi-
cation.
(DOCX)
Table S7 Data from GWAS catalog for associations with
strictly matching phenotypes. PMID: PubMed ID. RA-
F=risk allele frequency. OR/Beta=odds ratio or beta (effect size).
CI=confidence interval.
(DOCX)
Table S8 Data from GWAS catalog for successful
associations without strictly matching phenotypes.
PMID: PubMed ID. RAF=risk allele frequency. OR/Beta=odds
ratio or beta (effect size). CI=confidence interval.
(DOCX)
Acknowledgments
We would like to thank the customers of 23andMe for their enthusiasm and
continued participation in this research. We are also grateful to all the
employees of 23andMe, who together have made this research possible.
Special thanks to Krisztina Marton for survey development; Matthew
Crenson and Erin Cline Davis for writing and editing help on the surveys;
Andro Hsu for obtaining human subjects approval; Joseph Cackler, Chris
Cheng, Russell D’Sa, Cary Kempston, Alex Khomenko, Marcela
Miyazawa, Mike Polcari, and Angel Steger for their work on the
development and implementation of 23andWe—23andMe’s research
arm. We would like to thank employees at the National Genetics Institute
for their work on sample processing and genotyping. Finally, we thank Stan
Nelson, Russ Altman, and Michael Eisen, all members of our scientific
advisory board, for comments on our surveys.
Author Contributions
Conceived and designed the experiments: JYT CBD DAH AKK JMM
ABC UF BTN JLM AW NE. Performed the experiments: JYT CBD NE.
Analyzed the data: JYT CBD NE. Contributed reagents/materials/
analysis tools: JYT CBD AKK JMM ABC BTN NE. Wrote the paper: JYT
CBD NE.
Efficient Replication of over 180 Associations
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23473References
1. Bilder RM, Sabb FW, Cannon TD, London ED, Jentsch JD, et al. (2009)
Phenomics: the systematic study of phenotypes on a genome-wide scale.
Neuroscience 164: 30–42. doi:10.1016/j.neuroscience.2009.01.027.
2. Houle D, Govindaraju DR, Omholt S (2010) Phenomics: the next challenge.
Nat Rev Genet 11: 855–866. doi:10.1038/nrg2897.
3. Lee K, Sawcer S (2010) Detecting genes in complex disease: does phenotype
accuracy limit the horizon? Trends Genet 26: 241–242; author reply 242–243.
doi:10.1016/j.tig.2010.03.003.
4. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ (2004)
Agreement between self-report questionnaires and medical record data was
substantial for diabetes, hypertension, myocardial infarction and stroke but not
for heart failure. J Clin Epidemiol 57: 1096–1103. doi:10.1016/j.jcli-
nepi.2004.04.005.
5. Smith B, Chu LK, Smith TC, Amoroso PJ, Boyko EJ, et al. (2008) Challenges of
self-reported medical conditions and electronic medical records among members
of a large military cohort. BMC Med Res Methodol 8: 37. doi:10.1186/1471-
2288-8-37.
6. O’Mahony PG, Dobson R, Rodgers H, James OF, Thomson RG (1995)
Validation of a population screening questionnaire to assess prevalence of stroke.
Stroke 26: 1334–1337.
7. Walker MK, Whincup PH, Shaper AG, Lennon LT, Thomson AG (1998)
Validation of patient recall of doctor-diagnosed heart attack and stroke: a postal
questionnaire and record review comparison. Am J Epidemiol 148: 355–361.
8. Martin LM, Leff M, Calonge N, Garrett C, Nelson DE (2000) Validation of self-
reported chronic conditions and health services in a managed care population.
Am J Prev Med 18: 215–218.
9. Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, et al. (1986)
Validation of questionnaire information on risk factors and disease outcomes in a
prospective cohort study of women. Am J Epidemiol 123: 894–900.
10. Burgess AM, Martel MU, Wyman DK (1971) Validation of interview-based
disease classifications: a mail survey of physicians. J Chronic Dis 24: 45–59.
11. Eriksson N, Macpherson JM, Tung JY, Hon LS, Naughton B, et al. (2010) Web-
based, participant-driven studies yield novel genetic associations for common
traits. PLoS Genet 6: e1000993. doi:10.1371/journal.pgen.1000993.
12. Genome.gov | A Catalog of Published Genome-Wide Association Studies (n.d.)
Available: http://www.genome.gov/gwastudies/. Accessed 17 Nov 2010.
13. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009)
Potential etiologic and functional implications of genome-wide association loci
for human diseases and traits. Proc Natl Acad Sci U S A 106: 9362–9367.
doi:10.1073/pnas.0903103106.
14. Latiano A, Palmieri O, Valvano MR, D’Inca ` R, Cucchiara S, et al. (2008)
Replication of interleukin 23 receptor and autophagy-related 16-like 1
association in adult- and pediatric-onset inflammatory bowel disease in Italy.
World J Gastroenterol 14: 4643–4651.
15. Illumina .::. Investor Relations 2011 Press Releases (n.d.) Available: http://investor.
illumina.com/phoenix.zhtml?c=121127&p=irol-news&nyo=0. Accessed 28 Jun
2011.
16. Pelchat ML, Bykowski C, Duke FF, Reed DR (2011) Excretion and perception
of a characteristic odor in urine after asparagus ingestion: a psychophysical and
genetic study. Chem Senses 36: 9–17. doi:10.1093/chemse/bjq081.
17. Medland SE, Nyholt DR, Painter JN, McEvoy BP, McRae AF, et al. (2009)
Common variants in the trichohyalin gene are associated with straight hair in
Europeans. Am J Hum Genet 85: 750–755. doi:10.1016/j.ajhg.2009.10.009.
18. Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, et al. (2011) Web-based
genome-wide association study identifies two novel loci and a substantial genetic
component for Parkinson’s disease. PLoS Genetics;In press.
19. The International Parkinson’s Disease Genetics Consortium (2011) A two-stage
meta-analysis identifies several new loci for Parkinson’s disease. PLoS
Genetics;In press.
20. Ritchie MD, Denny JC, Crawford DC, Ramirez AH, Weiner JB, et al. (2010)
Robust replication of genotype-phenotype associations across multiple diseases
in an electronic medical record. Am J Hum Genet 86: 560–572. doi:10.1016/
j.ajhg.2010.03.003.
21. Kraft P, Zeggini E, Ioannidis JPA (2009) Replication in genome-wide association
studies. Stat Sci 24: 561–573. doi:10.1214/09-STS290.
22. Xiao R, Boehnke M (2009) Quantifying and correcting for the winner’s curse in
genetic association studies. Genet Epidemiol 33: 453–462. doi:10.1002/
gepi.20398.
23. Feldman DE, Bernatsky S, Haggerty J, Leffondre ´ K, Tousignant P, et al. (2007)
Delay in consultation with specialists for persons with suspected new-onset
rheumatoid arthritis: a population-based study. Arthritis Rheum 57: 1419–1425.
doi:10.1002/art.23086.
24. Pinto Sa ´nchez MI, Smecuol E, Va ´zquez H, Mazure R, Maurin ˜o E, et al. (2009)
Very high rate of misdiagnosis of celiac disease in clinical practice. Acta
Gastroenterol Latinoam 39: 250–253.
25. Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, et al. (2003) Prevalence of
celiac disease in at-risk and not-at-risk groups in the United States: a large
multicenter study. Arch Intern Med 163: 286–292.
26. Freidlin B, Zheng G, Li Z, Gastwirth JL (2002) Trend tests for case-control
studies of genetic markers: power, sample size and robustness. Hum Hered 53:
146–152.
27. Gasperini C (2001) Differential diagnosis in multiple sclerosis. Neurol Sci 22
Suppl 2: S93–97.
28. Kronz JD, Westra WH, Epstein JI (1999) Mandatory second opinion surgical
pathology at a large referral hospital. Cancer 86: 2426–2435.
29. Pritchard JK, Przeworski M (2001) Linkage disequilibrium in humans: models
and data. Am J Hum Genet 69: 1–14. doi:10.1086/321275.
30. Bierut LJ, Agrawal A, Bucholz KK, Doheny KF, Laurie C, et al. (2010) A
genome-wide association study of alcohol dependence. Proc Natl Acad Sci U S A
107: 5082–5087. doi:10.1073/pnas.0911109107.
31. Genome-wide association study of 14,000 cases of seven common diseases and
3,000 shared controls (2007) Nature 447: 661–678. doi:10.1038/nature05911.
32. Sklar P, Smoller JW, Fan J, Ferreira MAR, Perlis RH, et al. (2008) Whole-
genome association study of bipolar disorder. Mol Psychiatry 13: 558–569.
doi:10.1038/sj.mp.4002151.
33. Ferreira MAR, O’Donovan MC, Meng YA, Jones IR, Ruderfer DM, et al.
(2008) Collaborative genome-wide association analysis supports a role for ANK3
and CACNA1C in bipolar disorder. Nat Genet 40: 1056–1058. doi:10.1038/
ng.209.
34. Scott LJ, Muglia P, Kong XQ, Guan W, Flickinger M, et al. (2009) Genome-
wide association and meta-analysis of bipolar disorder in individuals of
European ancestry. Proc Natl Acad Sci U S A 106: 7501–7506. doi:10.1073/
pnas.0813386106.
35. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, et al. (2009) A genome-wide
association study in chronic obstructive pulmonary disease (COPD): identifica-
tion of two major susceptibility loci. PLoS Genet 5: e1000421. doi:10.1371/
journal.pgen.1000421.
36. Van Durme YMTA, Eijgelsheim M, Joos GF, Hofman A, Uitterlinden AG,
et al. (2010) Hedgehog-interacting protein is a COPD susceptibility gene: the
Rotterdam Study. Eur Respir J 36: 89–95. doi:10.1183/09031936.00129509.
37. Pillai SG, Kong X, Edwards LD, Cho M, Anderson WH, et al. (2010) Loci
Identified by Genome-wide Association Studies Influence Different Disease-
related Phenotypes in COPD. Am J Respir Crit Care Med;Available: http://
www.ncbi.nlm.nih.gov/pubmed/20656943. Accessed 17 Nov 2010.
38. McGovern DPB, Jones MR, Taylor KD, Marciante K, Yan X, et al. (2010)
Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn’s
disease. Hum Mol Genet 19: 3468–3476. doi:10.1093/hmg/ddq248.
39. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, et al. (2007)
Genome-wide association study identifies new susceptibility loci for Crohn
disease and implicates autophagy in disease pathogenesis. Nat Genet 39:
596–604. doi:10.1038/ng2032.
40. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, et al. (2010) A
large-scale, consortium-based genomewide association study of asthma.
N Engl J Med 363: 1211–1221. doi:10.1056/NEJMoa0906312.
41. Simo ´n-Sa ´nchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2009)
Genome-wide association study reveals genetic risk underlying Parkinson’s
disease. Nat Genet 41: 1308–1312. doi:10.1038/ng.487.
42. Chang M, Li Y, Yan C, Callis-Duffin KP, Matsunami N, et al. (2008) Variants
in the 5q31 cytokine gene cluster are associated with psoriasis. Genes Immun 9:
176–181. doi:10.1038/sj.gene.6364451.
43. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, et al. (2009) Genome-wide
scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat
Genet 41: 199–204. doi:10.1038/ng.311.
44. Perdigones N, Lamas JR, Vigo AG, de la Concha EG, Jover JA, et al. (2009)
6q23 polymorphisms in rheumatoid arthritis Spanish patients. Rheumatology
(Oxford) 48: 618–621. doi:10.1093/rheumatology/kep053.
45. Patsopoulos NA, Ioannidis JPA (2010) Susceptibility variants for rheumatoid
arthritis in the TRAF1-C5 and 6q23 loci: a meta-analysis. Ann Rheum Dis 69:
561–566. doi:10.1136/ard.2009.109447.
46. Ioannidis JPA, Patsopoulos NA, Evangelou E (2007) Heterogeneity in meta-
analyses of genome-wide association investigations. PLoS ONE 2: e841.
doi:10.1371/journal.pone.0000841.
47. Takahashi M, Saenko VA, Rogounovitch TI, Kawaguchi T, Drozd VM, et al.
(2010) The FOXE1 locus is a major genetic determinant for radiation-related
thyroid carcinoma in Chernobyl. Hum Mol Genet 19: 2516–2523. doi:10.1093/
hmg/ddq123.
48. Barrett JC, Lee JC, Lees CW, Prescott NJ, Anderson CA, et al. (2009) Genome-
wide association study of ulcerative colitis identifies three new susceptibility loci,
including the HNF4A region. Nat Genet 41: 1330–1334. doi:10.1038/ng.483.
Efficient Replication of over 180 Associations
PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e23473